fibrinogen concentrate + Placebo
Phase 1/2Withdrawn 0 watching 0 views this week⚡ Active
40
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Postpartum Hemorrhage
Conditions
Postpartum Hemorrhage
Trial Timeline
Jan 1, 2021 → Dec 1, 2021
NCT ID
NCT02528708About fibrinogen concentrate + Placebo
fibrinogen concentrate + Placebo is a phase 1/2 stage product being developed by CSL for Postpartum Hemorrhage. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02528708. Target conditions include Postpartum Hemorrhage.
Hype Score Breakdown
Clinical
13
Activity
8
Company
9
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02528708 | Phase 1/2 | Withdrawn |
Competing Products
20 competing products in Postpartum Hemorrhage
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Misoprostol + Oxytocin | Cipla | Phase 3 | 77 |
| Quetiapine | AstraZeneca | Phase 2 | 52 |
| Azithromycin + Azithromycin and amoxicillin + Placebo | Merck | Approved | 85 |
| Eptacog alfa (NovoSeven) | Novo Nordisk | Approved | 84 |
| Eptacog alfa (activated) | Novo Nordisk | Pre-clinical | 22 |
| aripiprazole | Bristol Myers Squibb | Phase 3 | 76 |
| SAGE-217 15/20 mg Oral Solution + Placebo + SAGE 217 30 mg Capsules | Biogen | Phase 3 | 74 |
| SAGE-217 + Placebo | Biogen | Phase 3 | 74 |
| Zuranolone | Biogen | Pre-clinical | 20 |
| Zuranolone | Biogen | Pre-clinical | 20 |
| LPCN 1154A + Placebo | Lipocine | Phase 3 | 69 |
| Goserelin 3.6 mg implant + Placebo | Brain Biotech | Pre-clinical | 15 |
| ZULRESSO (brexanolone) injection | Supernus Pharmaceuticals | Pre-clinical | 18 |
| Placebo + SAGE-547 90 μg/kg/h | Supernus Pharmaceuticals | Phase 3 | 72 |
| ZULRESSO® | Supernus Pharmaceuticals | Approved | 80 |
| SAGE-547 | Supernus Pharmaceuticals | Phase 2 | 47 |
| Placebo + SAGE-547 60 μg/kg/h + SAGE-547 90 μg/kg/h | Supernus Pharmaceuticals | Phase 3 | 72 |
| SAGE-547 + Placebo | Supernus Pharmaceuticals | Phase 2 | 47 |
| GH001 | GH Research | Phase 2 | 47 |
| Brexanolone | Brain Biotech | Pre-clinical | 15 |